ORPHA:319218
Ebola hemorrhagic fever
Also known as: EHF · Ebola fever · Ebola virus disease
Publications
66,466
Trials
89
Interventional, condition-specific
Researchers
1,452
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Ebola hemorrhagic fever (EHF), caused by Ebola virus, is a severe viral hemorrhagic disease characterized by initial fever and malaise followed by gastrointestinal symptoms, bleeding, shock, and multi-organ system failure.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005737
- MeSH:D019142
- UMLS:C0282687
- NCIT:C36171
Additional Mondo synonyms (4)
Ebola · Ebolavirus caused disease or disorder · Ebolavirus disease or disorder · Ebolavirus infectious disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
66,466 matched papers (51,639 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
89 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
66,466
66,466 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
66,466 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
51,639 in the last 10 years · low confidence
Phrase hits: 66,466 · MeSH hits: 175
Who's working on it?
1,452
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02Mbala-Kingebeni P6 papers · 2026
National Institute for Biomedical Research, Kinshasa, Democratic Republic of Congo.
Papers in Europe PMC - 03
- 04Zeng X5 papers · 2026
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, United States of America.
Papers in Europe PMC - 05Ahuka-Mundeke S4 papers · 2026
Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.
Papers in Europe PMC - 06Carroll MW4 papers · 2026
Pandemic Sciences Institute & Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Papers in Europe PMC - 07
- 08Fashina T4 papers · 2025
Ophthalmology and Visual Sciences, University of Nebraska Medical Centre College of Medicine, Omaha, Nebraska, USA.
Papers in Europe PMC - 09
- 10Hayek BR4 papers · 2025
Ophthalmology and Visual Sciences, University of Nebraska Medical Centre College of Medicine, Omaha, Nebraska, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
89
interventional trials for this specific condition
89 interventional trials matched this specific condition name; 5 currently recruiting in our sample. 47 trials are registered for hemorrhagic fever, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
89 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.3th percentile).
low confidence · 98.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
89 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06841614·NOT YET RECRUITING·EBOla Post-Exposure Prophylaxis
Conditions: Ebola Virus Disease·Matched via name phrase
- NCT06126822·RECRUITING·Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Conditions: Ebola Virus Disease·Matched via name phrase
- NCT06587503·NOT YET RECRUITING·Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Conditions: Ebola Virus Disease · COVID-19·Matched via name phrase
- NCT05202288·NOT YET RECRUITING·Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Conditions: Ebola Virus Disease·Matched via name phrase
- NCT05909358·NOT YET RECRUITING·Solidarity/Tokomeza Ebola Trial
Conditions: Sudan Ebola Virus Vaccines·Matched via name phrase
Broader category: hemorrhagic fever
47
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07543458·NOT YET RECRUITING·Therapeutics for Moderate and Severe Dengue
Conditions: Dengue · Severe Dengue · Mosquito-Borne Diseases · Vector Borne Diseases·Matched via name phrase
- NCT06860334·NOT YET RECRUITING·UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF
Conditions: Crimean-Congo Hemorrhagic Fever·Matched via name phrase
- NCT06799013·RECRUITING·Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
Conditions: Vaccine · Crimean-Congo Hemorrhagic Fever·Matched via name phrase
Observational and natural-history studies
16 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07681752·NOT YET RECRUITING·Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
Conditions: Ebola Hemorrhagic Fever · Lassa Hemorrhagic Fever·Matched via name phrase
- NCT07688083·NOT YET RECRUITING·Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
Conditions: Ebola Hemorrhagic Fever·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Ebola hemorrhagic fever" OR "Ebola fever" OR "Ebola virus disease" OR "Ebola" OR "Ebolavirus infectious disease"
MeSH descriptor terms unioned into the query: Hemorrhagic Fever, Ebola
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Ebola hemorrhagic fever" OR "Ebola fever" OR "Ebola virus disease" OR "Ebola" OR "Ebolavirus infectious disease" OR "Hemorrhagic Fever, Ebola"
Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 89 interventional · 16 observational · 2 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemorrhagic fever"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: EHF; Ebolavirus caused disease or disorder; Ebolavirus disease or disorder
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (66466) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T13:19:03.087Z